Navigation Links
Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.
Date:11/18/2009

rly indicated," said Stephen Tyring, MD, PhD, Clinical Professor at the University of Texas Health Sciences Center, the lead investigator of the study.

There were no differences in significant adverse events between valomaciclovir and valacyclovir groups. The most common adverse event in all patient groups was nausea. No patient discontinued treatment due to adverse events related to EPB-348 use.

"We are pleased with our Phase 2b results that demonstrate once-daily EPB-348 is both safe and active in treating shingles. We are encouraged by the trends to better pain resolution and less severe pain in the valomaciclovir-treated patients. We anticipate that EPB-348 may be the first once-a-day shingles drug with a wider treatment window and a reduction in both the incidence and severity of shingles associated pain. We look forward to demonstrating these and other additional benefits in Phase 3 clinical trials," said Fred Volinsky, MD, Epiphany Biosciences' CEO.

EPB-348 has also been shown to be effective against acute infectious mononucleosis, for which there is no FDA-approved treatment, in a Phase 2a study. Data from this study were presented during the 2009 ICAAC meeting in San Francisco.

About EPB-348

EPB-348 is a potent inhibitor of herpes viruses, including the varicella zoster and Epstein-Barr viruses. It has been studied clinically in both shingles and infectious mononucleosis.

About Shingles

Shingles is a reactivation of the varicella zoster virus, the same virus that causes chickenpox in children, and infects over 90% of the US adult population. An estimated 5 in 1000 people suffer from shingles in the US every year, and 20% of all individuals are estimated to experience at least one episode of shingles during their lifetime. The risk of shingles outbreak dramatically increases with age.

Shingles manifests itself as a painful rash that develop into blis
'/>"/>

SOURCE Epiphany Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
(Date:7/24/2014)... , July 24, 2014  The American ... is supporting its mission to help address audit ... and exclusive agreement to be the information technology ... As the leading provider of billing and business ... unmatched HME industry expertise to support this important ...
(Date:7/24/2014)... , July 24, 2014  In any given hospital ... 25 patients has at least one hospital-acquired infection, according ... more, many of these infections prove fatal. And as ... alarming number of patient deaths per year, infection control ... Consequently, a stronger emphasis is being ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
... Computer Company (PCC) – a Vermont pediatric software developer ... updated 5010 transaction standard for electronic claims and claims ... among its payers. An ICD-10/5010 Readiness Survey ... Systems Society (HIMSS), indicates an estimated 1/3 of health ...
... Masimo (NASDAQ: MASI ) announced today that it ... 2, 2011, after the market closes on May 3, 2011. ... 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by ... Raad, Executive Vice President and Chief Financial Officer. A ...
Cached Medicine Technology:PCC Frustrated with Payers' Lack of 5010 Readiness 2Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011 2Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011 3
(Date:7/25/2014)... Washington, DC (PRWEB) July 25, 2014 ... against some health plans for providing inadequate access to ... serious threats to the health and safety of beneficiaries ... of drug coverage determinations, and CMS is taking quick ... 5, the Atlantic Information Services webinar, “Avoiding Costly ...
(Date:7/25/2014)... iTanSmart is a patented iOS suntan ... provides a tailored approach to eliminating the guesswork from ... skin damage. In his review, Eaton had positive things ... iTanSmart. , Eaton begins his commentary ... organized’ and ‘great alternative’ to its related Android competitor. ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer ... casual party dresses . According to the company’s ... now offered at discounted prices, up to 59% off. ... August 04. , Most of the casual party ... market. They are popular for special designs, delicate craftsmanship ...
(Date:7/24/2014)... For rats bearing human breast tumors, exposure to ... the breast cancer drug tamoxifen, according to data published ... American Association for Cancer Research. The negative effects of ... giving rats a melatonin supplement during the night. , ... with hormone receptor-positive breast cancer," said Steven M. Hill, ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... new analysis, it is better to give radiation therapy before ... well as surgery can reduce the risk of recurrence. Generally ... In Scandinavia and the Netherlands, the therapy is given before ... until afterwards.// ,An analysis of 8000 patients, led ...
... The diagnosis and treatment of epilepsy is often handled ... per cent of UK epilepsy patients not receiving appropriate ... epilepsy each year, and of these, about one-third can ... from the Institute of Neurology at University College London ...
... temperatures can lead to heat exhaustion and eventually to ... the temperature rises into the thirties. By the time ... ,Heat exhaustion refers to overheating of the ... rare cases, salt depletion. People who suffer from heat ...
... by cancer patients undergoing high-dose chemotherapy could be eased ... drugs used to fight cancer can prove extremely debilitating ... various anti-emetic drugs to lessen the reaction, but in ... a possible extra help. ,Acupuncture involves the insertion of ...
... Patients' experience of illness is being collected on a database ... ingredient in medical research is the patient's voice. It is ... researchers could learn a lot from the patient's ideas, beliefs ... too - showing they're not alone, and giving them vital ...
... able to treat the neurological problems that are common ... suffer from kidney failure, which is usually caused by ... leads to neurological complications like fatigue, apathy, emotional instability ... at the University of California at Irvine have learned ...
Cached Medicine News:
... The Bledsoe Lever Lock Knee Brace ... extension lock of the arthroscopic ACL ... allow motion for rehabilitation or passive ... locked "rigidly" in full extension for ...
The Bledsoe Basic Knee Brace offers a broad range of features that are unmatched by any other brace in its price range. Application of this brace is the easiest of any brace on the market....
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
Medicine Products: